000			02122 a2200553 4500
005			20250515020938.0
264		0	_c20060428
008			200604s 0 0 ger d
022			_a0935-8943
024	7		_a10.1055/s-2005-921107 _2doi
040			_aNLM _beng _cNLM
100	1		_aHennemann, B
245	0	0	_a[Palliative chemotherapy of head and neck cancer: present status and future development]. _h[electronic resource]
260			_bLaryngo- rhino- otologie _cMar 2006
300			_a172-8 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_aAnimals
650	0	4	_aAntimetabolites, Antineoplastic _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Agents, Phytogenic _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCisplatin _xadministration & dosage
650	0	4	_aClinical Trials as Topic
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDisease Progression
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aForecasting
650	0	4	_aGefitinib
650	0	4	_aHead and Neck Neoplasms _xdrug therapy
650	0	4	_aHumans
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aPalliative Care
650	0	4	_aPatient Selection
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aQuinazolines _xadministration & dosage
650	0	4	_aRats
650	0	4	_aTaxoids _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aVinblastine _xadministration & dosage
650	0	4	_aVinorelbine
650	0	4	_aGemcitabine
773	0		_tLaryngo- rhino- otologie _gvol. 85 _gno. 3 _gp. 172-8
856	4	0	_uhttps://doi.org/10.1055/s-2005-921107 _zAvailable from publisher's website
999			_c16156053 _d16156053